Transient lymphopenia has been reported previously in a clinical trial of a ChAd63-vectored Leishmania vaccine; however, in this study it was attributed to a predominant reduction in the frequency of CD4+ T cells (59). The gene discussed is CD4; the disease is lymphopenia.